Loading clinical trials...

Real-World Study of PADN for the Treatment of PAH | Clinical Trials | Clareo Health

RECRUITING

Real-World Study of PADN for the Treatment of PAH

Real-World Study of Percutaneous Pulmonary Artery Denervation (PADN) for the Treatment of Pulmonary Arterial Hypertension (PAH)

NCT07039604•Pulnovo Medical (Wuxi) Co., Ltd.

View on ClinicalTrials.gov

Summary

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Diagnosed with PAH and received PADN procedure since March 2024.
•2. No contraindications to procedure.
•3. Able to provide informed consent and authorize use of health/research data.
•4. Compliant with treatment and follow-up requirements.

Exclusion Criteria

•None specified.

Locations (1)

The First Affiliated Hospital with Nanjing Medical University

Nanjing, Jiangsu, China

Key Dates

Start Date

March 19, 2025

Primary Completion Date

December 30, 2028

Completion Date

December 30, 2028

Last Updated

June 26, 2025

Enrollment

200

ESTIMATED participants

Conditions

Pulmonary HypertensionHypertension, Pulmonary Arterial

Interventions

Enhancor™ Radiofrequency Catheter, Pulnovo Medical (Wuxi) CO., Ltd., Wuxi, Jiangsu, China

DEVICE

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

NCT07073820

Pulmonary Hypertension

View study

RECRUITINGPHASE1

Preliminary Human Trials of F230 Tablets

NCT06899815

Pulmonary Hypertension

View study

RECRUITINGPHASE2/PHASE3

Sildinafil in Pulmonary Hypertension-Rheumatic Chronic Valvular Disease(RCT)

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 26, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Real-World Study of PADN for the Treatment of PAH

Inclusion Criteria

Exclusion Criteria

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

Preliminary Human Trials of F230 Tablets

Sildinafil in Pulmonary Hypertension-Rheumatic Chronic Valvular Disease(RCT)

Prospective Evaluation of AI-ECG for SHD Detection

Pulmonary Hypertension in Left Heart Disease

CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH